Role of hormones in pilosebaceous unit development

Endocrine Reviews

Volumn 21, Issue 4, 2000, Pages 363-392

  Deplewski, Dianne ^a,b   Rosenfield, Robert L ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ESTROGEN; GLUCOCORTICOID; GROWTH HORMONE; INSULIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; RETINOID; SOMATOMEDIN; THYROID HORMONE;

ACNE VULGARIS; ALOPECIA; CELL DIFFERENTIATION; CELL GROWTH; EMBRYO DEVELOPMENT; GENE CLUSTER; HAIR FOLLICLE; HAIR GROWTH; HIRSUTISM; HOMEOBOX; MOLECULAR GENETICS; ONTOGENY; ORGAN CULTURE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SEBACEOUS GLAND;

EID: 0034453088     PISSN: 0163769X     EISSN: None     Source Type: Journal    
DOI: 10.1210/edrv.21.4.0404     Document Type: Review

References (357)

1. Pilosebaceous physiology in relation to hirsutism and acne
2. Role of androgens in the developmental biology of the pilosebaceous unit
3. Quantitative measurement of a secondary sex character, axillary hair
4. The control of hair growth: An overview
5. Predictors of severity of acne vulgaris in young adolescent girls: Results of a five-year longitudinal study
6. Acne, hirsutism, and alopecia in adolescent girls. Clinical expressions of androgen excess
7. Expression of morphogens during human follicle development in vivo and a model for studying follicle morphogenesis in vitro
8. Dermal-epidermal interactions
9. Hair
10. Glucose-6-phosphate dehydrogenase mosaicism: Utilization in the study of hair follicle variegation
11. Epidermal-dermal interactions during formation of skin and cutaneous appendages
12. The secret life of the hair follicle
13. Retinoic acid and mouse skin morphogenesis. II. Role of epidermal competence in hair glandular metaplasia
14. Lymphoid enhancer factor I directs hair follicle patterning and epithelial cell fate
15. Development of several organs that require inductive epithelial-mesenchymal interactions is impaired in LEF-l-deficient mice
16. An introduction to sebaceous glands
17. Hair follicle growth controls
18. De Novo hair follicle morphogenesis and hair tumors in mice expressing a truncated β-catenin in skin
19. Fibroblast growth factor and epidermal growth factor in hair development
20. Epidermal growth factor delays the development of the epidermis and hair follicles of mice during growth of the first coat
21. Effects of anti-EGF serum on newborn mice
22. Localization of epidermal growth factor immunoreactivity in sheep skin during wool follicle development
23. Distribution of epidermal growth factor receptors in rat tissues during embryonic skin development, hair formation, and the adult hair growth cycle
24. Immunolocalization of epidermal growth factor receptors in normal developing human skin
25. Physiological effects of transforming growth factor in the newborn mouse
26. Involvement of bone morphogenetic protein-4 (BMP-4) and Vgr-1 in morphogenesis and neurogenesis in the mouse
27. Organogenesis and pattern formation in the mouse: RNA distribution patterns suggest a role for bone morphogenetic protein-2A (BMP-2A)
28. Epidermal mosaicism producing localised acne: Somatic mutation in FGFR2
29. Expression and role of E- and P-cadherin adhesion molecules in embryonic histogenesis. II. Skin morphogenesis
30. Epimorphin: A mesenchymal protein essential for epithelial morphogenesis
31. Wnt-7a in feather morphogenesis: Involvement of anterior-poste rior asymmetry and proximal-distal elongation demonstrated with an in vitro reconstitution model
32. Sonic hedgehog signaling is essential for hair development
33. Homeobox genes and skin development: A review
34. Homeobox genes in embryogenesis and pathogenesis
35. Retinoids and vertebrate development
36. Adhesion molecules and homeoproteins in the phenotypic determination of skin appendages
37. Differential expression of the Hox 3.1 gene in adult mouse skin
38. HOX homeobox genes exhibit spatial and temporal changes in expression during human skin development
39. Glandular metaplasia of hair follicles and other responses to vitamin A excess in cultures of rodent skin
40. Mechanism of skin morphogenesis. II. Retinoic acid modulates axis orientation and phenotypes of skin appendages
41. Human hair growth in vitro
42. Labebretaining cells reside in the bulge area of pilosebaceous unit: Implications for follicular stem cells, hair cycle, and skin carcinogenesis
43. Androgens and the hair follicle. Cultured human dermal papilla cells as a model system
44. Control of the hair cycle and hair diseases as cycling disorders
45. The dermal papilla and the development and growth of hair
46. Induction of hair growth by implantation of cultured dermal papilla cells
47. Trans-gender induction of hair follicles
48. Hair follicle stem cells: Their location, role in hair cycle, and involvement in skin tumor formation
49. Histologic study of the regeneration of axillary hair after removal with subcutaneous tissue shaver
50. Analysis of apoptosis during hair follicle regression (catagen)
51. Towards defining the pathogenesis of the hairless phenotype
52. Alopecia universalis associated with a mutation in the human hairless gene
53. Apoptosis in normal skin
54. Androgen induction of fob licular epithelial cell growth is mediated via insulin-like growth factor-I from dermal papilla cells
55. Effects of insulin and insulin-like growth factors on cultured human hair follicles: IGF-I at physiologic concentrations is an important regulator of hair follicle growth in vitro
56. Growth factors and cytokines in hair follicle development and cycling: Recent insights from animal models and the potentials for clinical therapy
57. The function of KGF in morphogenesis of epithelium and reepithelialization of wounds
58. Fibroblast growth factor signalling in the hair growth cycle: Expression of the fibroblast growth factor receptor and ligand genes in the murine hair follicle
59. FGF5 as a regulator of the hair growth cycle: Evidence from targeted and spontaneous mutations
60. The use of dermal papilla cells in studies of normal and abnormal hair follicle biology
61. Autografs in alopecia and other selected dermatologic conditions
62. Clinical longitudinal standards for height and height velocity for North American children
63. New cell formation in human sebaceous glands
64. Reconstitution of hair follicle development in vivo: Determination of follicle formation, hair growth, and hair quality by dermal cells
65. The effects of isotretinoin on follicular and sebaceous gland differentiation
66. Inhibitory effects of 13-cis-retinoic acid on human sebaceous glands
67. Meibomian gland morphology and tear osmolarity: Changes with accutane therapy
68. Organ maintenance of human sebaceous glands: In vitro effects of 13-cis retinoic acid and testosterone
69. Sebumsuppressing activity of the nonpolar arotinoid Ro 15-0778 in rodents
70. Actions of isotretinoin and etretinate on the pilosebaceous unit
71. Pathogenesis of blepharoconjunctivitis complicating 13-cis-retinoic acid (isotretinoin) therapy in a laboratory model
72. Stromalepithelial interactions in adult organs
73. Human pilosebaceous culture
74. Whole hair follicle culture
75. The isolation and maintenance of the human pilosebaceous unit
76. The improved organ maintenance of the human sebaceous gland: Modeling in vitro the effects of epidermal growth factor, androgens, estrogens, 13-cis retinoic acid, and phenol red
77. Epidermal differentiation: The bare essentials
78. Retinoids as important regulators of terminal differentiation: Examining keratin expression in individual epidermal cells at various stages of keratinization
79. The use of retinoic acid to probe the relation between hyperproliferation-associated keratins and cell prolifera tion in normal and malignant epidermal cells
80. Keratinocyte growth factor. A fibroblast growth factor family member with unusual target cell specificity
81. Human keratinocyte growth factor activity on proliferation and differentiation of human keratmocytes: Differentiation response distinguishes KGF from EGF family
82. Growth of sebaceous cells in monolayer culture
83. Mechanisms of androgen induction of sebocyte differentiation
84. Culture of hair matrix and follicular keratinocytes
85. Studies of androgen metabolism and action in cultured hair and skin cells
86. Vibrissa dermal papilla cell aggregative behaviour in vivo and in vitro
87. Dermal-epidermal interactionsfollicle-derived cell populations in the study of hair-growth mechanisms
88. Culture of cells derived from the human sebaceous gland under serum-free conditions without a biological feeder layer or specific matrices
89. Culture of human sebocytes and markers of sebocytic differentiation in vitro
90. Isolation of human sebaceous glands and cultivation of sebaceous gland-derived cells as an in vitro model
91. Establishment and characterization of an immortalized human sebaceous gland cell line (SZ95)
92. Relationship of sebaceous cell stage to growth in culture
93. Sebaceous gland differentiation. I. Separation, morphology and lipogenesis of isolated cells from the mouse preputial gland tumor
94. Androgen receptor expression in the preputial gland and its sebocytes
95. Characterization of human sebaceous cells in vitro
96. Cyclic AMP-receptor protein activity in rat preputial cells
97. Sebaceous gland differentiation. III. The uses and limitations of freshly isolated mouse preputial gland cells for the in vitro study of hormone and drug action
98. Retinoid effects on sebocyte proliferation Methods Enzymol
99. Isolation and maintenance of the human pilosebaceous duct: 13-cis retinoic acid acts directly on the duct in vitro
100. Structural and lipid biochemical correlates of the epidermal permeability barrier
101. Is increased 5α-reductase activity a primary phenomenon in androgen-dependent skin disorders?
102. Characterization of 5α-reductase in cultured human dermal papilla cells from beard and occipital scalp hair
103. Delta 5-3 beta-hydroxysteroid dehydrogenase activity in sebaceous glands of scalp in male-pattern baldness
104. Sebaceous gland activity and serum dehydroepiandrosterone sulfate levels in boys and girls
105. Acne vulgaris in premenarchal girls. An early sign of puberty associated with rising levels of dehydroepiandrosterone
106. Distribution of androgen metabolizing enzymes in isolated tissues of human forehead and axillary skin
107. Activity of testosterone 5α-reductase in various tissues of human skin
108. Activity of 17 β-hydroxysteroid dehydrogenase in various tissues of human skin
109. Biologic effects of hyperandrogenemia in polycystic ovary syndrome
110. Immunohistochemical distribution of aromatase and 3β-hydroxysteroid dehydrogenase in human hair follicle and sebaceous gland
111. The relationship between the in vitro activity of 3β-hydroxysteroid dehydrogenase Δ 4-5-isomerase in human sebaceous glands and their secretory activity in vivo
112. Expression of mRNA for androgen receptor, 5α-reductase and 17βhydroxysteroid dehydrogenase in human dermal papilla cells
113. Oxidative activity of the type 2 isozyme of 17β-hydroxysteroid dehydrogenase (17β-HSD) predominates in human sebaceous glands
114. Androgen metabolism in sebaceous glands from subjects with and without acne
115. The molecular genetics of steroid 5α-reductases
116. Steroid 5α-reductase 2 deficiency
117. Tissue distribution and kinetic characteristics of rat steroid 5α-reductase isozymes
118. The molecular genetics of steroid 5α-reductase
119. Selective retention of dihydrotestosterone by prostatic nuclei
120. The intranuclear binding of testosterone and 5α-androstan-17-β-ol-3-one by rat prostate
121. Feed-forward control of prostate growth: Dihydrotestosterone induces expression of its own biosynthetic enzyme, steroid 5α-reductase
122. Influence of steroid hormones on 5α-reductase activity in female and male genital skin fibroblasts in culture
123. Dihydrotestosterone stimulates 5α-reductase activity in public skin fibroblasts
124. Tissue distribution and ontogeny of steroid 5αreductase isozyme expression
125. Deletion of steroid 5α-reductase 2 gene in male pseudohermaphroditism
126. Immunohistochemical localization of types I and 25α-reductase in human scalp
127. The androgen control of sebum production. Studies of subjects with dihydrotestosterone deficiency and complete androgen insensitivity
128. Preputial sebocyte 5αreductase isoform specificity
129. The nuclear receptor superfamily: The second decade
130. Distinguishing androgen receptor agonists and antagonists: Distinct mechanisms of activation by medroxyprogesterone acetate and dihydrotestosterone
131. Specificity of ligand-dependent androgen receptor stabilization: Receptor domain interactions influence ligand dissociation and receptor stability
132. Localization of androgen receptors in human skin by immunohistochemistry: Implications for the hormonal regulation of hair growth, sebaceous glands and sweat glands
133. Location of androgen receptor in human skin
134. Immunocytochemical localization of androgen receptors in human skin using monoclonal antibodies against the androgen receptor
135. Hormones and hair growth: Variations in androgen receptor content of dermal papilla cells cultured from human and red deer (Cervus elaphus) hair follicles
136. Mechanism of action of androgen in dermal papilla cells
137. Balding hair follicle dermal papilla cells contain higher levels of androgen receptors than those from non-balding scalp
138. Control of human sebocyte proliferation in vitro by testosterone and 5α-dihydrotestosterone is dependent on the localization of the sebaceous glands
139. Spironolactone directly inhibits proliferation of cultured human facial sebocytes and acts antagonistically to testosterone and 5α-dihydrotestosterone in vitro
140. Androgens affect the activity of human sebocytes in culture in a manner dependent on the localization of the sebaceous glands and their effect is antagonized by spironolactone
141. Growth hormone and insulin-like growth factors have different effects on sebaceous cell growth and differentiation
142. Rat preputial sebocyte differentiation involves peroxisome proliferator-activated receptors
143. Androgen receptor (AR) and paradoxical response to androgen of cultured preputial sebocytes
144. Progressive differentiation of human sebocytes in vitro is characterized by increasing cell size and altering antigen expres sion and is regulated by culture duration and retinoids
145. Modification of lipogenesis in the isolated hamster flank organ through clofibfic acid
146. Suppression of sebaceous gland activity with eicosa-5:8:11:14-tetraynoic acid
147. PPAR: A mediator of peroxisome proliferator action
148. The peroxisome proliferator activated receptors (PPARs) and their effects on lipid metabolism and adipocyte differentiation
149. The RXR heterodimers and orphan receptors
150. An overview of acne
151. Essential fatty acids and acne
152. Topical tretinoin for hair growth promotion
153. Effect of retinoids on follicular cells
154. Retinoids: Compounds important to hair growth
155. Altered proliferation, synthetic activity, and differentiation of cultured human sebocytes in the absence of vitamin A and their modulation by synthetic retinoids
156. Effects of 13-cis-retinoic acid, all-trans-retinoic acid, and acitretin on the proliferation, lipid synthesis and keratin expression of cultured human sebocytes in vitro
157. Identification of a receptor for the morphogen retinoic acid
158. Nuclear receptor that identifies a novel retinoic acid response pathway
159. Purification, cloning, and RXR identify of the HeLa cell factor with which RAR or TR heterodimerizes to bind target sequences efficiently
160. Cellular localization of retinoic acid receptor-γ expression in normal and neoplastic skin
161. In situ detection of retinoid-X receptor expression in normal and psoriatic human skin
162. Cloning of murine α and β retinoic acid receptors and a novel γ predominantly expressed in skin
163. Dermal papilla cells from human hair follicles express mRNA for retinoic acid receptors in culture
164. 9-cis Retinoic acid is a high affinity ligand for the retinoid X receptor
165. 9-cis retinoic acid stereoisomer binds and activates the nuclear receptor RXRα
166. A human retinoic acid receptor which belongs to the family of nuclear receptors
167. Effect of retinoid treatment of rats on hepatic microsomal metabolism and cytochromes P450
168. RAR-, not RXR, ligands inhibit cell activation and prevent apoptosis in B-lymphocytes
169. Retinoid X receptor-specific retinoids inhibit the ability of retinoic acid receptor-specific retinoids to increase the level of insulin-like growth factor binding protein-3 in human ectocervical epithelial cells
170. Alltrans-retinoic acid inhibits Jun N-terminal kinase-dependent signaling pathways
171. Retinoids increase human apolipoprotein A-11 expression through activation of the retinoid X receptor but not the retinoic acid receptor
172. Alltrans and 9-cis retinoic acid induction of CRABP II transcription is mediated by RAR-RXR heterodimers bound to DR1 and DR2 repeated motifs
173. 3
174. RXRβ: A coregulator that enhances binding of retinoic acid, thyroid hormone, and vitamin D receptors to their cognate response elements
175. Homodimer formarion of retmoid X receptor induced by 9-cis retinoic acid
176. Convergence of 9-cis retinoic acid and peroxisome proliferator signalling pathways through heterodimer formation of their receptors
177. Inhibition of adipogenesis through MAP kinase-mediated phosphorylation of PPARγ
178. Site-related specificities of the control by androgenic status of adipogenesis and mitogen-activated protein kinase cascade/c-fos signaling pathways in rat preadipocytes
179. Activation of retinoid X receptors induces apoptosis in HL-60 cell lines
180. The role of specific retinoid receptors in sebocyte growth and differentiation in culture
181. Limited cooperation between peroxisome proliferator-activated receptors and retinoid X receptors in induction of sebocyte differentiation and proliferation
182. Anabolic and androgenic effect of testosterone on sexually immature boys and its dependency on growth hormone
183. Growth hormone substitution in adult growth hormone-deficient men augments androgen effects on the skin
184. Hormones and hair patterning in men: A role for insulin-like growth factor 17
185. A longitudinal study of the relationship of plasma somatomedin-C concentration to the pubertal growth spurt
186. Sebum excretion in acromegaly
187. The effects of hypophysectomy and of bovine growth hormone on the responses to testosterone of prostate, preputial, harderian and lachrymal glands and of brown adipose tissue in the rat
188. The sebotrophic action of growth hormone (BGH) in the rat
189. Effects of adrenocorticotrophic hormone, growth hormone, prolactin, adrenalectomy and corticoids upon the weight, protein and nucleic acid content of the female rat preputial glands
190. Growth hormone promotes the differentiation of myoblasts and preadipocytes generated by azacytidine treatment of 10T1/2 cells
191. A dual effector theory of growth-hormone action
192. Mechanism of the stimulatory effect of growth hormone on longitudinal bone growth
193. The mechanisms by which growth hormone brings about growth. The relative contributions of growth hormone and insulin-like growth factors
194. Localization of the growth hormone receptor/binding protein in skin
195. Demonstration and localization of growth hormone receptor in human skin and skin fibroblasts
196. Cellular localization of the growth hormone binding protein in the rat
197. Ontogeny of growth hormone receptors in human tissues: An immunohistochemical study
198. Immunohistochemical localization of insulin-like growth factor I in the adult rat
199. The insulin-like growth factor I receptor is expressed by epithelial cells with proliferative potential in human epidermis and skin appendages: Correlation of increased expression with epidermal hyperplasia
200. In vivo cytokine and receptor gene expression during the rat hair growth cycle. Analysis by semi-quantitative RT-PCR
201. Androgen induction of steroid 5-α-reductase may be mediated via insulin-like growth factor-I
202. Hormone-induced disorders of hair growth
203. Methods for growth of cultured cells in serum-free medium
204. Observations on the growth and metabolic functions of cultured cells derived from human adipose tissue
205. Insulin stimulates in vivo cell proliferation in white adipose tissue
206. Insulin-like growth factors I and II: Peptide, messenger ribonucleic acid and gene structures, serum and tissue concentrations
207. Primary structure of human insulin-like growth factor II
208. The amino acid sequence of human insulin-like growth factor I and its structural homology with proinsulin
209. Insulin-like growth factors and their binding proteins: Biological actions
210. Prolonged maintenance of human hair follicles in vitro in a serum-free medium
211. The human sebocyte culture model provides new insights into development and management of seborrhoea and ache
212. Clinical review 74: Dermatological manifestations of endocrine disorders
213. Skin manifestations of Cushing disease in children and adolescents before and after the resolution of hypercortisolemia
214. Cortisol alters the effects of growth hormone (GH) and insulin-like growth factor -I (IGF-I) on sebaceous epithelial cell (sebocyte) growth and differentiation
215. Estrogen treatment of hair disorders
216. The effects of prolonged physiologic estradiol therapy on the maturation of hypogonadal teen-agers
217. Regulation of cytoplasmic dihydrotestosterone binding in dog prostrate by 17β-estradiol
218. Physiologic testosterone or estradiol induction of puberty increases plasma somatomedin-C
219. Effect of pregnancy on the human hair cycle
220. Pathologic dynamics of human hair loss
221. The effect of androgens and estrogens on human sebaceous glands
222. The local effects of topically applied estradiol, cyproterone acetate, and ethanol on sebaceous secretion in intact male rats
223. Effectiveness of norgestimate and ethinyl estradiol in treating moderate acne vulgaris
224. Multiple androgenic abnormalities, including elevated free testosterone, in hyperprolactinemic women
225. Effects of prolactin and progesterone on preputial gland growth and progesterone metabolism in hypophysectomized, ovariectomized immature rats
226. Distribution of prolactin receptor immunoreactivity in ovine skin and changes during the wool follicle growth cycle
227. Hair diameter in female baldness
228. Hair growth and alopecia in hypothyroidism
229. Hormonal control and methods of measuring sebaceous gland activity
230. Immunohistochemical localization of thyroid hormone nuclear receptors in human hair follicles and in vitro effect of L-triiodothyronine on cultured cells of hair follicles and skin
231. Thyroid hormone receptor β1 is expressed in the human hair follicle
232. A parathyroid hormone antagonist stimulates epidermal proliferation and hair growth in mice
233. PTHrP regulates epidermal differentiation in adult mice
234. Overexpression of parathyroid hormone related protein in the skin of transgenic mice interferes with hair follicle development
235. 3 in skin
236. 3 receptors during the murine hair cycle
237. Calcitriol-resistant rickets with alopecia
238. Targeted ablation of the vitamin D receptor: An animal model of vitamin D-dependent rickets type II with alopecia
239. Normalization of mineral ion homeostasis by dietary means prevents hyperparathyroidism, rickets, and osteomalacia, but not alopecia in vitamin D receptor-ablated mice
240. Exocrine gland dysfunction in MC5-R-deficient mice: Evidence for coordinated regulation of exocrine gland function by melanocortin peptides
241. Plasma testosterone binding globulin and indexes of the Concentration of unbound plasma androgens in normal and hirsute subjects
242. Female hirsutism: Pathophysiological considerations and therapeutic implications
243. The relationship of mild hirsutism or ache in women to androgens
244. Acne vulgaris in early adolescent boys. Correlations with pubertal maturation and age
245. Acne vulgaris
246. Propionibacterium levels in patients with and without acne vulgaris
247. The chemoattractant properties of comedonal components
248. Report of the consensus conference on acne classification
249. Plasma androgens in women with acne vulgaris
250. Elevated free testosterone levels in women with acne
251. Androgen excess in cystic acne
252. Differential rates of conversion of testosterone to dihydrotestosterone in acne and in normal human skin
253. Androgen excess in women with acne alone compared with women with acne and/or hirsutism
254. Diagnostic and predictive value of horizontal sections of scalp biopsy specimens in male pattern androgenetic alopecia
255. Biology of scalp hair growth
256. Male pattern baldness: Classification and incidence
257. The midline part: An important physical clue to the clinical diagnosis of androgenetic alopecia in women
258. The prevalence of hyperandrogenism in 109 consecutive female patients with diffuse alopecia
259. Evidence for a single gene effect causing polycystic ovaries and male pattern baldness
260. Androgenetic alopecia: An autosomal dominant disorder
261. Treatment of hair loss
262. The inheritance of polycystic ovarian disease and a possible relationship to premature balding
263. Polycystic ovaries and premature male pattern baldness are associated with one allele of the steroid metabolism gene CYP17
264. Polycystic ovaries are inherited as an autosomal dominant trait: Analysis of 29 polycystic ovary syndrome and 10 control families
265. Hyperhydrosis as the only manifestation of hyperandrogenism in an adolescent girl
266. Ovarian and adrenal function in polycystic ovary syndrome
267. Obesity and oligomenorrhea are associated with hyperandrogenism independent of hirsutism
268. Amenorrhea with cryptic hyperandrogenemia
269. Genetic and hormonal characterization of cryptic 21-hydroxylase deficiency
270. 5α-Reductase activity in the genital skin of hirsute women
271. Regulation of androgen receptor and 5αreductase in the skin of normal and hirsute women
272. Activity of the type 1 5α-reductase exhibits regional differences in isolated sebaceous glands and whole skin
273. Dihydrotestosterone is a peripheral paracrine hormone
274. Serum levels of 3α-androstanediol glucuronide in hirsute and non hirsute women
275. Two different pathogenetic mechanisms may play a role in acne and in hirsutism
276. Androgen conjugates: Physiology and clinical significance
277. Clinical relevance of testosterone and dihydrotestosterone metabolism in women
278. Androgenic adrenal hyperfunction in acromegaly
279. Insulin resistance in polycystic ovarian syndrome
280. Insulin resistance in nonobese patients with polycystic ovary syndrome
281. Acanthosis nigricans in obese women with hyperandrogenism. Characterization of an insulin-resistant state distinct from the type A and B syndromes
282. Polycystic ovary syndrome: Symptomatology, pathophysiology, and epidemiology
283. Abnormalities in the serum insulin-like growth factor-1 axis in women with hyperandrogenism
284. Androgen receptor characteristics in skin fibroblasts from hirsute women
285. Size polymorphisms of the androgen receptor among female Hispardcs and correlation with androgenic characteristics
286. Androgen receptor-mediated hypersensitivity to androgens in women with nonhyperandrogenic hirsutism: Skewing of X-chromosome inactivation
287. The role of the CAG repeat polymorphism in the androgen receptor gene and of skewed X-chromosome inactivation in the pathogenesis of hirsutism
288. Dynamics of suppression and recovery of plasma FSH, LH, androstenedione and testosterone in polycystic ovarian disease using an oral contraceptive
289. Biologic effects of various doses of ethinyl estradiol in postmenopausal women
290. Plasma levels of adrenocorticotropin and cortisol in women receiving oral contraceptive steroid treatment
291. Adrenal function in hirsutism. II. Effect of an oral contraceptive
292. Animal biological assessment
293. Hormonal and nonhormonal factors affecting sex hormone-binding globulin levels in blood
294. Comparative pharmacology of newer progestogens
295. The use of oestrogen-progestogen preparations in the treatment of hirsutism in the female
296. Norgestimate and ethinyl estradiol in the treatment of acne vulgaris: A randomized, placebo-controlled trial
297. Differential suppression of testosterone and estradiol in hirsute women with the superacfive gonadotropinreleasing hormone agonist leuprolide
298. Prospective randomized study comparing the long-acfing gonadotropin-releasing hormone agonist triptorelin, flutamide, and cyproterone acetate, used in combination with an oral contraceptive, in the treatment of hirsutism
299. The effect of a gonadotropin-releasing hormone agonist analog (nafarelin) on bone metabolism
300. Reversible trabecular bone density loss following induced hypo-oestrogenism with the GnRH analogue buserelin in premenopausal women
301. Potential utility of gonadotropin-releasing hormone agonists in the management of ovarian hyperandrogenism
302. Mechanism of inhibition of human tesficular steroidogenesis by oral ketoconazole
303. Kinetic analysis of inhibition of human adrenal steroidogenesis by ketoconazole
304. Ketoconazole therapy for women with acne and/or hirsutism
305. Sensitivity of corfisol and adrenal androgens to dexamethasone suppression in hirsute women
306. Effect of daily and alternate day low dose prednisone on serum cortisol and adrenal androgens in hirsute women
307. Peripheral androgen blockade vs. glandular androgen suppression in the treatment of hirsutism
308. Cyproterone acetate vs. hydrocortisone treatment in late-onset adrenal hyperplasia
309. The effects of two doses of spironolactone on serum androgens and anagen hair in hirsute women
310. Comparison of spironolactone flutamide and finasteride efficacy in the treatment of hirsutism: A randomized double blind placebo-controlled trial
311. Effect of cyproterone acetate on hair growth, sebaceous secretion and endocrine parameters in a hirsute subject
312. Treatment of hirsutism with spironolactone
313. The influence of cyproterone-acetate orally on the hair root status in women with idiopathic hirsutism
314. Androgen metabolism in hirsute patients treated with cyproterone acetate
315. Anti-androgen treatment in women with ache: A controlled trial
316. Treatment of hirsufism and ache with cyproterone acetate
317. Comparison of sequential cyproterone acetate/estrogen vs. spironolactone/oral contraceptive in the treatment of hirsutism
318. The use of human skin fibroblasts to obtain potency estimates of drug binding to androgen receptors
319. Oral spironolactone improves acne vulgaris and reduces sebum excretion
320. Oral spironolactone: An effective treatment for ache vulgaris in women
321. Comparison of the efficacy of spironolactone vs. flutamide in the treatment of hirsutism
322. Comparison of finasteride vs. spironolactone in the treatment of idiopathic hirsutism
323. A prospective randomized trial comparing finasteride to spironolactone in the treatment of hirsute women
324. Beneficial effect of spironolactone on androgenic alopecia
325. Estrogen antagonisms: Effects of several steroidal spironolactones on estrogen-induced uterine growth in mice
326. Effects of a novel nonsteroidal antiandrogen on canine prostatic hyperplasia
327. Treatment of hirsutism with the pure antiandrogen flutamide
328. Treatment of hirsutism in women with flutamide
329. Flutamide hepatotoxicity
330. A prospective randomized trial comparing low dose flutamide, finasteride, ketoconazole, and cyproterone acetate-estrogen regimens in the treatment of hirsutism
331. Clinical and hormonal effects of the 5α-reductase inhibitor finasteride in idiopathic hirsutism
332. Outcome of long-term treatment with the 5α-reductase inhibitor finasteride in idiopathic hirsutism: Clinical and hormonal effects during a 1-year course of therapy and 1-year follow-up
333. Finasteride in the treatment of men with androgenetic alopecia
334. Chronic treatment with finasteride daily does not affect spermatogenesis or semen production in young men
335. The effects of finasteride on scalp skin and serum androgen levels in men with androgenetic alopecia
336. The effects of finasteride on postmenopausal women with andogenetic alopecia
337. Current concepts of polycystic ovary syndrome
338. Acanthosis nigricans, insulin action, and hyperandrogenism: Clinical, histological, and biochemical findings
339. Improvement in endocrine and ovarian fimction during dietary treatment of obese women with polycystic ovary syndrome
340. Menstrual cyclicity after metformin therapy in polycystic ovary syndrome
341. Can mefformin reduce insulin resistance in polycystic ovary syndrome?
342. Therapeutic effects of metformin on insulin resistance and hyperandrogenism in polycystic ovary syndrome
343. Effects of metformin on insulin secretion, insulin action, and ovarian steroidogenesis in women with polycystic ovary syndrome
344. Metformin therapy improves the menstrual pattern with minimal endocrine and metabolic effects in women with polycystic ovary syndrome
345. Decreases in ovarian cytochrome P450c17 a activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome
346. Lean women with polycystic ovary syndrome respond to insulin reduction with decreases in ovarian P450c17 a activity and serum androgens
347. Weight control and its beneficial effect on fertility in women with obesity and polycystic ovary syndrome
348. Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy
349. Metformin therapy is associated with a decrease in plasma plasminogen activator inhibitor-1, lipoprotein(a), and immunoreactive insulin levels in patients with the polycystic ovary syndrome
350. Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome
351. Effect of troglitazone on endocrine and ovulatory performance in women with insulin resistance-related polycystic ovary syndrome
352. The insulin-sensitizing agent troglitazone improves metabolic and reproductive abnormahties in the polycystic ovary syndrome
353. Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome
354. Mechanism of metformin action in obese and lean noninsulin-dependent diabetic subjects
355. Effect of metformin on carbohydrate and lipoprotein metabolism in NIDDM patients
356. Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus
357. Thiazolidinediones in the treatment of insulin resistance and type II diabetes